Deal Snapshot
BRIDGE BIOTHERAPEUTICS ACQUIRES NEW DRUG CANDIDATE FROM KONKUK UNIVERSITY
Friday 07 February 2020

South Korea-based clinical stage biotech company Bridge Biotherapeutics Inc., has signed a collaboration and license agreement with Konkuk University in South Korea for a new drug development candidate for back-eye disorder treatments, the company said.
Total consideration for the transaction is KRW 10bn (USD 8.4m), including KRW 300m (USD 0.25m) in an upfront payment. The early-stage drug candidate in-licensed from Konkuk University is an inhibitor of undisclosed target proteins, discovered by the research team at KU.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 07/02/2020
Target: New drug development candidate for back-eye disorder treatments
Country: South Korea
Deal Size: 8.4m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor: Konkuk University
Buyer: Bridge Biotherapeutics Inc
Comment:


Options